Emma studied biochemistry at Imperial College London then stayed on for a Masters and PhD on her favourite topic, immunology. After almost a decade there, she braved the move out of London (a whole 12 miles south) and joined The Institute of Cancer Research to study multiple myeloma, a white blood cell cancer. She left the lab for the final time in 2010 and, after a couple of years at Breakthrough Breast Cancer, joined the Science Communications team at Cancer Research UK.
There’s more to stopping cancer from spreading than simply cutting out chocolate, despite what the headlines say.
On Ada Lovelace Day 2016, we speak to Dr Bissan Al-Lazikani about how she is using computers to help personalise cancer treatment.
We explore how clinical trials are run, and hear from a patient about what it’s like taking part in a cancer clinical trial.
Recent research has reinforced the need for all women with ovarian cancer to receive genetic testing, but they aren’t. We explore why.
Our scientists have revealed how a targeted skin cancer drug works, which could help tackle drug resistance.
Read about how we’re approaching the challenge of understanding and treating lung, pancreatic, oesophageal cancers and brain tumours.
Discussing how the idea for a new drug can come from many different avenues.